ImmuCell Corporation Cost, Depreciation, Amortization and Depletion
ImmuCell Corporation (ICCC) reported Cost, Depreciation, Amortization and Depletion of $679.04 thousand for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostDepreciationAmortizationAndDepletion · last filed 2025-08-14
- ImmuCell Corporation cost, depreciation, amortization and depletion for the quarter ending 2025-06-30 was $679.04K, a 0.40% decline year-over-year.
- ImmuCell Corporation cost, depreciation, amortization and depletion for the quarter ending 2025-03-31 was $686.77K, a 1.37% increase year-over-year.
- ImmuCell Corporation cost, depreciation, amortization and depletion for the quarter ending 2024-12-31 was $684.65K, a 0.05% decline year-over-year.
- ImmuCell Corporation cost, depreciation, amortization and depletion for the quarter ending 2024-09-30 was $685.93K, a 3.27% decline year-over-year.
- ImmuCell Corporation cost, depreciation, amortization and depletion for fiscal 2024 was $2.73M, a 0.36% decline from fiscal 2023.
- ImmuCell Corporation cost, depreciation, amortization and depletion for fiscal 2023 was $2.74M.
| Period end | Cost, Depreciation, Amortization and Depletion 3 month | Cost, Depreciation, Amortization and Depletion 6 month | Cost, Depreciation, Amortization and Depletion 9 month | Cost, Depreciation, Amortization and Depletion 12 month |
|---|---|---|---|---|
| 2025-06-30 | $679.04K 10-Q · filed 2025-08-14 | $1.37M 10-Q · filed 2025-08-14 | $2.05M derived: sum of 3 quarters · filed 2025-08-14 | $2.74M derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | $686.77K 10-Q · filed 2025-05-14 | $1.37M derived: sum of 2 quarters · filed 2025-05-14 | $2.06M derived: sum of 3 quarters · filed 2025-05-14 | $2.74M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-12-31 | $684.65K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $1.37M derived: sum of 2 quarters · filed 2025-03-28 | $2.05M derived: sum of 3 quarters · filed 2025-08-14 | $2.73M 10-K · filed 2025-03-28 |
| 2024-09-30 | $685.93K 10-Q · filed 2024-11-13 | $1.37M derived: sum of 2 quarters · filed 2025-08-14 | $2.05M 10-Q · filed 2024-11-13 | $2.73M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-06-30 | $681.76K 10-Q · filed 2025-08-14 | $1.36M 10-Q · filed 2025-08-14 | $2.04M derived: sum of 3 quarters · filed 2025-08-14 | $2.75M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $677.50K 10-Q · filed 2025-05-14 | $1.36M derived: sum of 2 quarters · filed 2025-05-14 | $2.07M derived: sum of 3 quarters · filed 2025-05-14 | $2.76M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $684.98K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $1.39M derived: sum of 2 quarters · filed 2025-03-28 | $2.08M derived: sum of 3 quarters · filed 2025-03-28 | $2.74M 10-K · filed 2025-03-28 |
| 2023-09-30 | $709.10K 10-Q · filed 2024-11-13 | $1.40M derived: sum of 2 quarters · filed 2024-11-13 | $2.05M 10-Q · filed 2024-11-13 | $2.66M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $686.71K 10-Q · filed 2024-08-13 | $1.35M 10-Q · filed 2024-08-13 | $1.95M derived: sum of 3 quarters · filed 2024-11-13 | $2.59M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-03-31 | $658.83K 10-Q · filed 2024-05-14 | $1.27M derived: sum of 2 quarters · filed 2024-11-13 | $1.90M derived: sum of 3 quarters · filed 2024-11-13 | $2.53M derived: sum of 4 quarters · filed 2024-11-13 |
| 2022-12-31 | $606.17K derived: 10-Q 12 month − 10-Q 9 month · filed 2024-11-13 | $1.24M derived: sum of 2 quarters · filed 2024-11-13 | $1.87M derived: sum of 3 quarters · filed 2024-11-13 | $2.50M 10-Q · filed 2024-11-13 |
| 2022-09-30 | $634.24K 10-Q · filed 2023-11-13 | $1.27M derived: sum of 2 quarters · filed 2023-11-13 | $1.89M 10-Q · filed 2023-11-13 | $2.49M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $631.30K 10-Q · filed 2023-08-10 | $1.25M 10-Q · filed 2023-08-10 | $1.86M derived: sum of 3 quarters · filed 2023-11-13 | $2.48M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-03-31 | $623.53K 10-Q · filed 2023-05-11 | $1.23M derived: sum of 2 quarters · filed 2023-11-13 | $1.85M derived: sum of 3 quarters · filed 2023-11-13 | $2.47M derived: sum of 4 quarters · filed 2023-11-13 |
| 2021-12-31 | $603.16K derived: 10-Q 12 month − 10-Q 9 month · filed 2023-11-13 | $1.22M derived: sum of 2 quarters · filed 2023-11-13 | $1.85M derived: sum of 3 quarters · filed 2023-11-13 | $2.47M 10-Q · filed 2023-11-13 |
| 2021-09-30 | $620.13K 10-Q · filed 2022-11-21 | $1.24M derived: sum of 2 quarters · filed 2022-11-21 | $1.87M 10-Q · filed 2022-11-21 | |
| 2021-06-30 | $624.26K 10-Q/A · filed 2022-11-21 | $1.25M 10-Q/A · filed 2022-11-21 | ||
| 2021-03-31 | $621.43K 10-Q/A · filed 2022-11-21 | |||
| 2020-12-31 | $2.45M 10-Q/A · filed 2022-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |